Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs.
Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs.
Expert Opin Drug Saf. 2020 Oct 22;:
Authors: Höybye C, Beck-Peccoz P, Simsek S, Zabransky M, Zouater H, Stalla G, Murray RD
Abstract
INTRODUCTION: Growth hormone (GH) deficiency (GHD) in adults is characterised by abnormal body composition, unfavourable cardiovascular risk factors and poor quality of life. The diagnosis is made within appropriate clinical settings and according to established guidelines. Numerous studies have shown that GH treatment improves body composition, cardiovascular risk factors, physical capacity and quality of life while issues on safety, in particular long-term safety, remain.
AREAS COVERED: Short- and long-term safety of GH replacement in adults with GHD.
EXPERT OPINION: Adults with GHD is an inhomogeneous group of patients and GH replacement requires individual considerations. Most adverse effects are mild and transient and related to fluid retention and GH dose. In patients without comorbidities long-term GH treatment is safe and development of diabetes, cardiovascular disease or tumours are not increased. Furthermore, mortality is not increased. Patients with risk factors should be identified before GH treatment is initiated and an optimal balance between benefit and risk established. Studies with sufficient duration and power to identify the development of cardiovas...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Diabetes | Drugs & Pharmacology | Endocrinology | Heart | Hormones | Study